JERUSALEM and NEEDHAM, Massachusetts, February 2 /PRNewswire-FirstCall/ -- Oridion Systems Ltd. (SIX Swiss Exchange: ORIDN). During the recent annual meeting of the Society for Technology in Anesthesia (STA) San Antonio, Texas, major new findings from numerous medical research projects demonstrating the clinical benefit of end-tidal CO2 (EtCO2) monitoring using Microstream(R) capnography technology were presented.
Research was presented on the new Oridion technology Integrated Pulmonary Index(TM), which utilizes end-tidal carbon dioxide (EtC02), Respiratory Rate, Pulse Rate and oxygen saturation (SpO2) to provide a clear inclusive assessment of a patient’s ventilatory status. A study conducted by David Gozal, MD from Hadassah University Hospital and Yaacov Gozal, MD from Shaare Zedek Medical Center, both in Jerusalem, on the validity and application of the Integrated Pulmonary Index(TM) in the pediatric population, concluded that it would be “particularly useful for non-expert personnel monitoring patients undergoing procedures requiring sedation or recovering from them”. An additional study carried out by Dr Yaacov Gozal on the reliability of this new software postoperatively concluded that since the Integrated Pulmonary Index(TM) (510K pending) is displayed as a single value, “it may simplify the monitoring of patients in a busy PACU.”
Several studies were also presented showing the unique Oridion family of CO2 breath sampling lines - FilterLine(R), and how they bring the superior Microstream(R) measuring technology to all patients in all settings. A study by Paul F. Nuccio, RRT and Michael R. Jackson, RRT-NPS from The Brigham and Woman’s Hospital in Boston on EtCO2 measurements with non-invasive ventilation (NIV), demonstrated that the oral/nasal Smart CapnoLine(R) H Plus CO2 sampling line “proved to be the most reliable” method “in trending EtCO2 with different ventilator settings and leak rates in the normal subject.”
The advantage of the Smart CapnoLine(R) H Plus O2 in sleep diagnostics was demonstrated by Peter L. Whitesell MD et al. This study showed that only the Oridion Smart CapnoLine(R) H Plus O2 met the “test objective of detecting changes associated with apnea and hypopnea”, and that it was “superior to other CO2 sampling lines, as it did not miss events”.
Benefits of another Oridion sampling line were shown in a study comparing CO2 sampling lines, which concluded that the Oridion Smart CapnoLine(R) Plus O2 “proved to be effective for EtCO2 sampling, providing accurate readings compared to other tested CO2 sampling lines with and without oxygen supply, when sampling from nose and mouth breathers”.
In an interesting application, the use of capnography on endangered animals was presented as well. A comprehensive research study conducted by Robin W. Radcliffe, DVM from Cornell University and others on the effect postural changes had on EtCO2 readings in the endangered African black rhinoceros and its importance to field anesthesia, concluded that EtCO2 monitoring could provide “important new information to enhance decision-making at this hazardous time [during anesthesia],” and that the results of the study “may be of interest in humans and their physiologic response to position [when sedated].”
“We are very pleased with the broad application of our products in research,” said Gerry Feldman, president of Oridion. “The studies presented at STA demonstrate the value of measuring end-tidal carbon dioxide to monitor ventilation as well as the importance of the FilterLine(R) CO2 sampling line by which exhaled gas is collected from the patient. We are further excited over the results of our Integrated Pulmonary Index from Israel. The new index is described in these reports as providing a simple and clinically useful approach to assessing the interactions of heart rate, oxygen saturation, respiratory rate and adequacy of ventilation.”
Oridion is the global leader of innovative capnography monitoring solutions helping to improve patient safety and its Microstream(R) capnography technology is the standard of care in ventilation monitoring.
A full list of the aforementioned studies presented at STA can be found on the Oridion website:
http://www.oridion.com/global/english/clinical_solutions/overview/
research.html
(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser’s URL address field. Remove the space if one exists.)
About Oridion
Oridion Systems Ltd. (http://www.oridion.comwww.oridion.com) is a global medical device company specializing in patient safety monitoring. The Company operates through wholly owned subsidiaries in the United States, Europe, and Israel.
Oridion develops proprietary medical devices and patient interfaces, based on its patented Microstream(R) technologies, for the enhancement of patient safety through the monitoring of the carbon dioxide (CO2) in a patient’s breath. These products provide effective, proven airway management and are used in various clinical environments, including procedural sedation, pain management, operating rooms, critical care units, post-anesthesia care units, emergency medical services, transport, alternate care and other settings where patients’ ventilation may be compromised and at risk.
Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “estimate” “project” “intend” “expect” “believe” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, our ability to maintain profits, the market demands for our Capnography products, our ability to focus our team on the Capnography business, changes in general economic and business conditions, inability to maintain market acceptance to the Company’s products, inability to timely develop and introduce new technologies, products and applications, rapid changes in the market for the Company’s products, loss of market share and pressure on prices resulting from competition, introduction of competing products by other companies, inability to manage growth and expansion, loss of key OEM partners, inability to attract and retain qualified personnel, inability to protect the Company’s proprietary technology.
Furthermore, this press release does not constitute an offer to sell or a solicitation of an offer to buy any securities. The Company’s shares issued have not been, and will not be, registered under the US Securities Act of 1933, as amended (the “Securities Act”), or under any of the relevant Securities Laws of any state of the United States. The Company’s shares may not be offered, sold or delivered, directly or indirectly, to, or for, the account of any US person (as defined in regulation S under the Securities Act) in or into the United States, or by use of the US mail, or by any means or instrumentality of United States interstate commerce, absent registration, or an exemption from registration under the Securities Act.
CONTACT: For further Oridion information please contact: Alan Adler,
Chairman and Chief Executive Officer, Walter Tabachnik, Chief Financial
Officer, Elena Gerberg, Investor Relations, e-mail: investor@oridion.com,
phone: +972-2-589-9159, address: Oridion Systems Ltd., P.O. Box 45025,
91450 Jerusalem, Israel
